ABEO

ABEO

USD

Abeona Therapeutics Inc. Common Stock

$6.245+0.045 (0.726%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$6.200

Máximo

$6.310

Mínimo

$6.100

Volumen

0.72M

Fundamentos de la Empresa

Capitalización de Mercado

319.5M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

1.67M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $3.93Actual $6.245Máximo $7.32

Noticias Relacionadas

Analyst Upgrades

Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19

Oppenheimer analyst Andreas Argyrides assumes Abeona Therapeutics with a Outperform rating and announces Price Target of $19.

Ver más
Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19
GlobeNewswire

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in

Ver más
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analyst Upgrades

Stifel Maintains Buy on Abeona Therapeutics, Lowers Price Target to $20

Stifel analyst Dae Gon Ha maintains Abeona Therapeutics with a Buy and lowers the price target from $21 to $20.

Ver más
Stifel Maintains Buy on Abeona Therapeutics, Lowers Price Target to $20
GlobeNewswire

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric

Ver más
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of

Ver más
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.